

Jan-Willem C Alffenaar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/814848/publications.pdf>

Version: 2024-02-01

281
papers

9,285
citations

46984

47
h-index

64755

79
g-index

285
all docs

285
docs citations

285
times ranked

7207
citing authors

#	ARTICLE	IF	CITATIONS
1	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. Intensive Care Medicine, 2020, 46, 1127-1153.	3.9	504
2	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	6.3	452
3	Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents. Clinical Infectious Diseases, 2009, 48, 1441-1458.	2.9	368
4	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. European Respiratory Journal, 2020, 56, 2001398.	3.1	273
5	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. European Respiratory Journal, 2014, 44, 23-63.	3.1	256
6	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. European Respiratory Journal, 2017, 49, 1700387.	3.1	233
7	Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2019, 41, 409-430.	1.0	188
8	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. Emerging Infectious Diseases, 2020, 26, 2709-2712.	2.0	133
9	Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. Clinical Infectious Diseases, 2018, 66, 1625-1630.	2.9	131
10	From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. Clinical Pharmacology and Therapeutics, 2021, 109, 928-941.	2.3	131
11	Therapeutic Drug Monitoring of Posaconazole: an Update. Current Fungal Infection Reports, 2016, 10, 51-61.	0.9	126
12	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020, 92, S15-S25.	1.5	126
13	Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 1063-1070.	1.2	117
14	Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. Journal of Infection, 2018, 77, 469-478.	1.7	114
15	Voriconazole metabolism is influenced by severe inflammation: a prospective study. Journal of Antimicrobial Chemotherapy, 2017, 72, 261-267.	1.3	113
16	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. European Respiratory Journal, 2019, 54, 1901522.	3.1	113
17	Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta, 2013, 115, 47-54.	2.9	110
18	Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis. Clinical Infectious Diseases, 2009, 49, 1080-1082.	2.9	91

#	ARTICLE	IF	CITATIONS
19	Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 39-44.	1.2	89
20	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	3.1	89
21	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	3.1	86
22	Inflammation Is Associated with Voriconazole Trough Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7098-7101.	1.4	81
23	Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization. <i>Current Pharmaceutical Design</i> , 2011, 17, 2931-2939.	0.9	72
24	Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2305-2313.	1.3	71
25	Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. <i>European Respiratory Journal</i> , 2011, 38, 888-894.	3.1	70
26	Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 229-234.	1.1	68
27	Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Linezolid in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5758-5763.	1.4	67
28	Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. <i>Talanta</i> , 2014, 121, 9-17.	2.9	62
29	Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 509-521.	1.5	62
30	The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. <i>Drugs</i> , 2019, 79, 161-171.	4.9	61
31	Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1287-1289.	1.4	59
32	Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. <i>European Respiratory Journal</i> , 2013, 42, 1614-1621.	3.1	59
33	What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis?. <i>Bioanalysis</i> , 2015, 7, 345-351.	0.6	59
34	Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. <i>European Respiratory Journal</i> , 2016, 47, 1867-1869.	3.1	59
35	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1774-1780.	2.9	59
36	Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 83-92.	1.0	59

#	ARTICLE	IF	CITATIONS
37	Limited Sampling Strategies for Therapeutic Drug Monitoring of Linezolid in Patients With Multidrug-Resistant Tuberculosis. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 97-101.	1.0	55
38	Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013, 42, 504-512.	3.1	55
39	Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2014, 43, 884-897.	3.1	55
40	New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	5.7	55
41	Management of patients with multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 645-662.	0.6	55
42	Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. <i>Clinical Infectious Diseases</i> , 2018, 67, S327-S335.	2.9	53
43	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. <i>Clinical Pharmacokinetics</i> , 2019, 58, 747-766.	1.6	53
44	Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies. <i>Npj Primary Care Respiratory Medicine</i> , 2020, 30, 21.	1.1	53
45	Determination of Moxifloxacin in Human Plasma, Plasma Ultrafiltrate, and Cerebrospinal Fluid by a Rapid and Simple Liquid Chromatography-Tandem Mass Spectrometry Method. <i>Journal of Analytical Toxicology</i> , 2010, 34, 135-141.	1.7	52
46	Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 533-544.	1.5	52
47	Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1771-1777.	1.2	51
48	Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2727-2731.	1.4	51
49	Omeprazole Significantly Reduces Posaconazole Serum Trough Level. <i>Clinical Infectious Diseases</i> , 2009, 48, 839-839.	2.9	50
50	Comparison of the Pharmacokinetics of Two Dosage Regimens of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients. <i>Clinical Pharmacokinetics</i> , 2010, 49, 559-565.	1.6	50
51	Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for <i>Mycobacterium ulcerans</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3878-3883.	1.4	49
52	Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. <i>Transplantation</i> , 2017, 101, 1727-1733.	0.5	49
53	Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. <i>European Respiratory Journal</i> , 2015, 46, 1205-1207.	3.1	47
54	Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 1585-1594.	1.9	46

#	ARTICLE	IF	CITATIONS
55	Dried Blood Spot Analysis Suitable for Therapeutic Drug Monitoring of Voriconazole, Fluconazole, and Posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4999-5004.	1.4	45
56	End TB with precision treatment!. <i>European Respiratory Journal</i> , 2016, 47, 680-682.	3.1	45
57	<scp>d</scp>-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. <i>Clinical Infectious Diseases</i> , 2018, 67, S308-S316.	2.9	45
58	Alternative Sampling Devices to Collect Dried Blood Microsamples: State-of-the-Art. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 310-321.	1.0	44
59	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2017, 23, 1718-1721.	2.0	43
60	A volumetric absorptive microsampling LC-MS/MS method for five immunosuppressants and their hematocrit effects. <i>Bioanalysis</i> , 2019, 11, 495-508.	0.6	43
61	Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	42
62	Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems. <i>Bioanalysis</i> , 2017, 9, 553-563.	0.6	42
63	The association between the <i>CYP2D6</i> genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2747-2760.	1.1	42
64	Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naïve TB patients: a randomized cross-over trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 703-710.	1.3	41
65	Low Caspofungin Exposure in Patients in Intensive Care Units. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	41
66	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	1.5	41
67	LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 34-40.	5.8	40
68	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. <i>Clinical Pharmacokinetics</i> , 2021, 60, 685-710.	1.6	39
69	Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis. <i>Clinical Infectious Diseases</i> , 2016, 62, civ921.	2.9	38
70	Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4907-4913.	1.4	37
71	Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 17-37.	1.0	37
72	Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. <i>International Journal of Infectious Diseases</i> , 2015, 32, 101-104.	1.5	36

#	ARTICLE	IF	CITATIONS
73	The performance of five different dried blood spot cards for the analysis of six immunosuppressants. <i>Bioanalysis</i> , 2015, 7, 1225-1235.	0.6	36
74	Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians. <i>Clinical Infectious Diseases</i> , 2017, 64, 104-105.	2.9	36
75	Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method. <i>Bioanalysis</i> , 2014, 6, 2125-2133.	0.6	35
76	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 688-694.	1.1	35
77	Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	33
78	Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 917-918, 1-4.	1.2	32
79	Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1755-1762.	1.3	32
80	Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis: Systematic Review of Randomized Controlled Trials. <i>Journal of Medical Internet Research</i> , 2022, 24, e33062.	2.1	32
81	Clarithromycin Significantly Increases Linezolid Serum Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5418-5419.	1.4	31
82	Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With Tuberculosis. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 350-354.	1.0	30
83	Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016, 47, 1229-1234.	3.1	30
84	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	1.7	30
85	Delamanid Resistance: Update and Clinical Management. <i>Clinical Infectious Diseases</i> , 2020, 71, 3252-3259.	2.9	30
86	Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2988-2994.	1.3	29
87	Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 766-771.	1.0	29
88	Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2336-2342.	1.4	29
89	Determination of Bedaquiline in Human Serum Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5675-5680.	1.4	28
90	Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 332-337.	1.1	28

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2691-2703.	1.3	28
92	Insufficient Fluconazole Exposure in Pediatric Cancer Patients and the Need for Therapeutic Drug Monitoring in Critically Ill Children. <i>Clinical Infectious Diseases</i> , 2014, 59, 1527-1533.	2.9	27
93	An interlaboratory quality control programme for the measurement of tuberculosis drugs. <i>European Respiratory Journal</i> , 2015, 46, 268-271.	3.1	27
94	Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response. <i>Clinical Infectious Diseases</i> , 2021, 73, e3520-e3528.	2.9	27
95	Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 23-39.	1.5	27
96	Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis setting: a qualitative study from the patient's perspective. <i>BMC Public Health</i> , 2021, 21, 1903.	1.2	27
97	Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach. <i>Current Pharmaceutical Design</i> , 2011, 17, 2900-2930.	0.9	26
98	Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs. <i>Clinical Infectious Diseases</i> , 2018, 67, S267-S273.	2.9	26
99	Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. <i>Clinical Infectious Diseases</i> , 2018, 67, S303-S307.	2.9	26
100	Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	26
101	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. <i>PLoS ONE</i> , 2016, 11, e0149768.	1.1	25
102	Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	25
103	Low but Sufficient Anidulafungin Exposure in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 304-308.	1.4	24
104	Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	24
105	Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1854-1862.	1.4	24
106	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 37-66.	0.5	24
107	Drug concentration in lung tissue in multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013, 42, 1750-1752.	3.1	23
108	Clinical Validation of the Analysis of Linezolid and Clarithromycin in Oral Fluid of Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3676-3680.	1.4	23

#	ARTICLE	IF	CITATIONS
109	Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3193-3195.	1.4	23
110	Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	23
111	Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. <i>Clinical Pharmacokinetics</i> , 2021, 60, 711-725.	1.6	23
112	Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 669-679.	1.1	23
113	High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 262-263.	1.1	22
114	<i>In Vitro</i> Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	22
115	Clinical standards for the dosing and management of TB drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 483-499.	0.6	22
116	Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. <i>Bioanalysis</i> , 2015, 7, 481-495.	0.6	21
117	Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300mg linezolid dosages using in-house made capsules. <i>European Respiratory Journal</i> , 2019, 54, 1900580.	3.1	21
118	Therapeutic Drug Monitoring: The Need for Practical Guidance. <i>Clinical Infectious Diseases</i> , 2019, 68, 1065-1066.	2.9	21
119	Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. <i>European Respiratory Journal</i> , 2015, 46, 444-455.	3.1	20
120	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. <i>European Respiratory Journal</i> , 2015, 45, 569-571.	3.1	20
121	Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601724.	3.1	20
122	Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. <i>International Journal of Tuberculosis and Lung Disease</i> , 2008, 12, 967-71.	0.6	20
123	Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1025-1037.	1.3	19
124	Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 11-21.	2.0	19
125	Bioavailability of voriconazole in hospitalised patients. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 243-246.	1.1	19
126	Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. <i>Clinical Infectious Diseases</i> , 2018, 67, 1743-1749.	2.9	19

#	ARTICLE	IF	CITATIONS
127	Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	19
128	Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1445-1454.	1.6	19
129	Tuberculosis-Related Malnutrition: Public Health Implications. <i>Journal of Infectious Diseases</i> , 2019, 220, 340-341.	1.9	19
130	Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 3529-3537.	2.6	19
131	Therapeutic Drug Monitoring of Ganciclovir: Where Are We?. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 138-147.	1.0	19
132	Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 109-113.	1.1	18
133	Global TB Network: working together to eliminate tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 347-349.	0.4	18
134	Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China. <i>European Respiratory Journal</i> , 2022, 59, 2101925.	3.1	18
135	Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 121-132.	1.0	18
136	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	1.5	18
137	Acquired Drug Resistance: We Can Do More Than We Think!. <i>Clinical Infectious Diseases</i> , 2015, 60, 969-970.	2.9	17
138	Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	17
139	Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations. <i>Mycoses</i> , 2019, 62, 698-705.	1.8	17
140	Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	17
141	Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs. <i>Clinical Mass Spectrometry</i> , 2019, 14, 34-45.	1.9	17
142	Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106180.	1.1	17
143	Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1158, 122397.	1.2	17
144	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601612.	3.1	16

#	ARTICLE	IF	CITATIONS
145	The effect of inflammation on voriconazole trough concentrations in children. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 678-680.	1.1	16
146	Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. <i>Drugs and Aging</i> , 2018, 35, 781-789.	1.3	16
147	A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 423-429.	1.3	16
148	Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. <i>Archives of Disease in Childhood</i> , 2022, 107, 70-77.	1.0	16
149	Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry. <i>Journal of Applied Bioanalysis</i> , 2015, 1, 89-98.	0.2	16
150	Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	15
151	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	1.2	15
152	Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	15
153	Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. <i>Transplant Infectious Disease</i> , 2012, 14, 440-443.	0.7	14
154	Trimethoprim/sulfamethoxazole susceptibility of <i>Mycobacterium tuberculosis</i> . <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 472-474.	1.1	14
155	Simultaneous Quantification of Anidulafungin and Caspofungin in Plasma by an Accurate and Simple Liquid Chromatography Tandem Mass-Spectrometric Method. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 778-784.	1.0	14
156	Quantification and Validation of Ertapenem Using a Liquid Chromatography-Tandem Mass Spectrometry Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3481-3484.	1.4	14
157	In vitro synergy between linezolid and clarithromycin against <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2014, 44, 808-811.	3.1	14
158	Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1700173.	3.1	14
159	Performance of a web-based application measuring spot quality in dried blood spot sampling. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1846-1853.	1.4	14
160	Predictors for treatment outcomes among patients with drug-susceptible tuberculosis in the Netherlands: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2019, 25, 761.e1-761.e7.	2.8	14
161	Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data. <i>Journal of Clinical Medicine</i> , 2021, 10, 2089.	1.0	14
162	Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 198-214.	1.0	14

#	ARTICLE	IF	CITATIONS
163	Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies. <i>Clinical Infectious Diseases</i> , 2022, 74, 2252-2260.	2.9	14
164	Dried Blood Spot Analysis Combined With Limited Sampling Models Can Advance Therapeutic Drug Monitoring of Tuberculosis Drugs. <i>Journal of Infectious Diseases</i> , 2012, 205, 1765-1766.	1.9	13
165	The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis. <i>Bioanalysis</i> , 2015, 7, 1717-1722.	0.6	13
166	Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 Countries. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 714-718.	1.0	13
167	Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients. <i>European Respiratory Journal</i> , 2019, 53, 1802107.	3.1	13
168	Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. <i>International Journal of Infectious Diseases</i> , 2020, 92, S5-S9.	1.5	13
169	Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1347-1358.	1.1	13
170	Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1547-1552.	1.3	13
171	Predictive Performance of Bayesian Vancomycin Monitoring in the Critically Ill*. <i>Critical Care Medicine</i> , 2021, 49, e952-e960.	0.4	13
172	Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106443.	1.1	13
173	Alternative Sampling Strategies for Therapeutic Drug Monitoring. , 2016, , 279-336.		12
174	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016, 47, 1288-1290.	3.1	12
175	Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3942-3947.	1.4	12
176	Emerging drugs and alternative possibilities in the treatment of tuberculosis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 103-116.	1.0	12
177	Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 68-73.	1.1	12
178	Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3292-3293.	1.8	12
179	Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1407-1417.	1.1	12
180	Antituberculosis Drug-induced Liver Injury in Children. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 50-53.	1.1	12

#	ARTICLE	IF	CITATIONS
181	Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2020, 59, 899-910.	1.6	12
182	Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. <i>European Respiratory Journal</i> , 2020, 55, 1901903.	3.1	12
183	Cefdinir and β -Lactamase Inhibitor Independent Efficacy Against <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Pharmacology</i> , 2021, 12, 677005.	1.6	12
184	Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in Indonesian tuberculosis patients. <i>International Journal of Mycobacteriology</i> , 2018, 7, 380.	0.3	12
185	Intravenous Voriconazole after Toxic Oral Administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2741-2742.	1.4	11
186	Immunoassay Analysis of Kanamycin in Serum Using the Tobramycin Kit. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4646-4651.	1.4	11
187	Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring. <i>International Journal of Mycobacteriology</i> , 2016, 5, S44-S45.	0.3	11
188	Pound foolish and penny wise—when will dosing of rifampicin be optimised?. <i>Lancet Respiratory Medicine</i> , 2018, 6, e11-e12.	5.2	11
189	Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands. <i>European Respiratory Journal</i> , 2019, 54, 1901402.	3.1	11
190	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020, 55, 1901908.	3.1	11
191	Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review.. <i>Frontiers in Pharmacology</i> , 2020, 11, 894.	1.6	11
192	Practices of therapeutic drug monitoring in tuberculosis: an international survey. <i>European Respiratory Journal</i> , 2022, 59, 2102787.	3.1	11
193	Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals. <i>Internal Medicine Journal</i> , 2022, 52, 1135-1143.	0.5	11
194	Clinical Validation of the Analysis of Fluconazole in Oral Fluid in Hospitalized Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6742-6746.	1.4	10
195	Limited-Sampling Strategies for Anidulafungin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1177-1181.	1.4	10
196	Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	10
197	In vitro evaluation of an intravenous microdialysis catheter for therapeutic drug monitoring of gentamicin and vancomycin. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00483.	1.1	10
198	Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	10

#	ARTICLE	IF	CITATIONS
199	Challenging the management of drug-resistant tuberculosis. <i>Lancet, The</i> , 2020, 395, 783.	6.3	10
200	Saliva-based linezolid monitoring on a mobile UV spectrophotometer. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1786-1792.	1.3	10
201	A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries. <i>Pulmonology</i> , 2022, 28, 44-58.	1.0	10
202	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.4	10
203	Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. <i>European Respiratory Journal</i> , 2016, 48, 1800-1802.	3.1	9
204	Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. <i>Lancet Infectious Diseases, The</i> , 2017, 17, 898.	4.6	9
205	Lack of penetration of amikacin into saliva of tuberculosis patients. <i>European Respiratory Journal</i> , 2018, 51, 1702024.	3.1	9
206	Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin. <i>Bioanalysis</i> , 2018, 10, 877-886.	0.6	9
207	Posaconazole trough concentrations are not influenced by inflammation: A prospective study. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 325-329.	1.1	9
208	Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China. <i>European Respiratory Journal</i> , 2021, 57, 2003463.	3.1	9
209	Determination of levofloxacin in human serum using liquid chromatography tandem mass spectrometry. <i>Journal of Applied Bioanalysis</i> , 2018, 4, 16-25.	0.2	9
210	Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients. <i>European Respiratory Journal</i> , 2016, 48, 1237-1239.	3.1	8
211	Comment on: Utility of voriconazole therapeutic drug monitoring: a meta-analysis: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3316-3317.	1.3	8
212	Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV. <i>European Respiratory Journal</i> , 2016, 48, 932-934.	3.1	8
213	Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	8
214	Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	8
215	Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. <i>European Respiratory Journal</i> , 2020, 56, 2000803.	3.1	8
216	Evaluation of target attainment of oral posaconazole suspension in immunocompromised children. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 726-729.	1.3	8

#	ARTICLE	IF	CITATIONS
217	Protocol for establishing an Adaptive Diseases control Expert Programme in Tanzania (ADEPT) for integrating care of communicable and non-communicable diseases using tuberculosis and diabetes as a case study. <i>BMJ Open</i> , 2021, 11, e041521.	0.8	8
218	Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 3-10.	1.0	8
219	Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2474-2474.	1.4	7
220	Statin Adjunctive Therapy for Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7004-7004.	1.4	7
221	Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702490.	3.1	7
222	Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study. <i>BMJ Open</i> , 2018, 8, e023899.	0.8	7
223	Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2848-2864.	1.3	7
224	Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. <i>European Respiratory Journal</i> , 2019, 54, 1900373.	3.1	7
225	<i>Mycobacterium tuberculosis</i> sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration. <i>International Journal of Infectious Diseases</i> , 2021, 104, 680-684.	1.5	7
226	Barriers to Optimal Tuberculosis Treatment Services at Community Health Centers: A Qualitative Study From a High Prevalent Tuberculosis Country. <i>Frontiers in Pharmacology</i> , 2022, 13, 857783.	1.6	7
227	Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. <i>PLoS ONE</i> , 2016, 11, e0166030.	1.1	6
228	Commemorating World TB Day 2020: "It's TIME" It's time to End the Global TB Epidemic. <i>International Journal of Infectious Diseases</i> , 2020, 92, S1-S4.	1.5	6
229	Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities. <i>European Respiratory Journal</i> , 2021, 57, 2002349.	3.1	6
230	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 466-473.	1.3	6
231	Clinical standards for drug-susceptible pulmonary TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 592-604.	0.6	6
232	Breakpoints and Drug Exposure Are Inevitably Closely Linked. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1384-1384.	1.4	5
233	Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. <i>European Respiratory Journal</i> , 2016, 48, 1230-1233.	3.1	5
234	Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2325-2329.	1.1	5

#	ARTICLE	IF	CITATIONS
235	Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 75, 441-448.	1.3	5
236	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 59-65.	1.0	5
237	Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?. <i>European Respiratory Journal</i> , 2019, 54, 1901508.	3.1	5
238	Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000606.	1.2	5
239	A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 943-953.	1.6	5
240	Patients and Medical Staff Attitudes Toward the Future Inclusion of eHealth in Tuberculosis Management: Perspectives From Six Countries Evaluated using a Qualitative Framework. <i>JMIR MHealth and UHealth</i> , 2020, 8, e18156.	1.8	5
241	Dosing of vancomycin and target attainment in neonates: a systematic review. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106515.	1.1	5
242	Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	5
243	Risk factors contributing to a low darunavir plasma concentration. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 456-461.	1.1	4
244	Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 2-2.	0.6	4
245	Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs. <i>Clinical Infectious Diseases</i> , 2019, 69, 2038-2039.	2.9	4
246	Respiratory Syncytial Virus Infection Morbidity in the Elderly: Time for Repurposing of Ribavirin?. <i>Clinical Infectious Diseases</i> , 2020, 70, 2238-2239.	2.9	4
247	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. <i>BMJ Open</i> , 2020, 10, e035350.	0.8	4
248	Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0182921.	1.4	4
249	Malnutrition assessment methods in adult patients with tuberculosis: a systematic review. <i>BMJ Open</i> , 2021, 11, e049777.	0.8	4
250	Precision Therapy for Invasive Fungal Diseases. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 18.	1.5	4
251	Raltegravir and rifampicin in patients with HIV and tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1046-1047.	4.6	3
252	Quantification of co-trimoxazole in serum and plasma using MS/MS. <i>Bioanalysis</i> , 2015, 7, 2741-2749.	0.6	3

#	ARTICLE	IF	CITATIONS
253	Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C<SUB>2h</SUB> measurements. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1695-1696.	0.6	3
254	Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. Journal of Antimicrobial Chemotherapy, 2019, 74, 691-698.	1.3	3
255	Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data. European Respiratory Journal, 2020, 56, 2001086.	3.1	3
256	Influence of age on real-life effects of doxycycline for acute exacerbations among COPD outpatients: a population-based cohort study. BMJ Open Respiratory Research, 2020, 7, e000535.	1.2	3
257	An Audit to Evaluate Vancomycin Therapeutic Drug Monitoring in a Neonatal Intensive Care Unit. Therapeutic Drug Monitoring, 2022, 44, 651-658.	1.0	3
258	Sertraline for HIV-associated cryptococcal meningitis. Lancet Infectious Diseases, The, 2016, 16, 1111.	4.6	2
259	Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	2
260	Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review. BMJ Open, 2020, 10, e034940.	0.8	2
261	Cross-validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Quantification of Levofloxacin in Saliva. Journal of Applied Bioanalysis, 2020, 6, 68-70.	0.2	2
262	Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). BMJ Open, 2022, 12, e054788.	0.8	2
263	A simple HPLC-UV Method for Therapeutic Drug Monitoring of Linezolid in human Plasma in low-resourced settings. Journal of Applied Bioanalysis, 2021, 7, e21008-e21008.	0.2	2
264	Treatment of Mycobacterium aviumâ€™intracellulare complex: a great leap forward. Journal of Antimicrobial Chemotherapy, 2017, 72, i1-i2.	1.3	1
265	Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. European Respiratory Journal, 2018, 51, 1702187.	3.1	1
266	Antifungal PK/PD in the Critically Ill. , 2018, , 213-238.		1
267	Repurposed Oral Ribavirin for Respiratory Virus Infections Requires Pharmacokinetic-pharmacodynamic Dose Optimization. Clinical Infectious Diseases, 2019, 70, 1258.	2.9	1
268	Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2019, 74, 834-834.	1.3	1
269	Measuring anti-TB drug concentrations in hair: unlocking the door to cumulative drug exposure and treatment outcome. International Journal of Tuberculosis and Lung Disease, 2021, 25, 3-5.	0.6	1
270	Reply to Van Daele et al., â€™Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?â€™. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	1

#	ARTICLE	IF	CITATIONS
271	Does Chemotherapy-Induced Gastrointestinal Mucositis Affect the Bioavailability and Efficacy of Anti-Infective Drugs?. <i>Biomedicines</i> , 2021, 9, 1389.	1.4	1
272	Monitoring during and after tuberculosis treatment. , 0, , 308-325.		1
273	The Never Ending Struggle Against Development of Drug Resistance. <i>Clinical Infectious Diseases</i> , 2015, 61, 137-138.	2.9	0
274	Reply to Verhaeghe et al: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 146-147.	2.9	0
275	Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 991-999.	0.6	0
276	1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?. <i>Open Forum Infectious Diseases</i> , 2019, 6, S560-S561.	0.4	0
277	Regimen design and pharmacokineticâ€“pharmacodynamic science: lessons learned. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 3-4.	4.6	0
278	Intermittent regimens for tuberculosis treatment: Back to the Future?. <i>European Respiratory Journal</i> , 2020, 56, 2002510.	3.1	0
279	Investigator-Initiated Studies in Infectious Diseasesâ€“Considerations for Pharmacokinetic-Pharmacodynamic Optimization. <i>Clinical Infectious Diseases</i> , 2021, 73, 1742.	2.9	0
280	Paediatric Acute Respiratory Distressâ€“Syndrome Neuromuscular Blockade study (PAN-study): a phase IV randomised controlled trial of early neuromuscular blockade in moderate-to-severe paediatric acute respiratory distress syndrome. <i>Trials</i> , 2022, 23, 96.	0.7	0
281	Real-World Effects of Antibiotic Treatment on Acute COPD Exacerbations in Outpatients: A Cohort Study under the PharmLines Initiative. <i>Respiration</i> , 2022, 101, 553-564.	1.2	0